Evaxion expands AI platform into autoimmune disease research
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
September 14, 2026 8:00 AM EDTAutoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology to target underlying pathologiesThe unique capabilities of AI-Immunology could potentially help develop new treatments with higher efficacy and less side effects than current treatmentsInitial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 2026
COPENHAGEN, Denmark, September 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (Evaxion), a clinical-stage TechBio company developing novel vaccines with its pioneering AI- Immunology platform, has begun the application... More



